Dhakal Hari P, McKenney Jesse K, Khor Li Yan, Reynolds Jordan P, Magi-Galluzzi Cristina, Przybycin Christopher G
Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Am J Surg Pathol. 2016 Feb;40(2):141-54. doi: 10.1097/PAS.0000000000000583.
Clear cell papillary renal cell carcinoma (CCPRCC) was recently included in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia as a subtype of RCC that is morphologically, immunohistochemically, and genetically distinct from both clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma. In our clinical practice we have observed tumors with overlapping histologic features of CCPRCC and CCRCC; therefore, our aim was to describe the morphologic, immunohistochemical, and clinical characteristics of these tumors. We examined a large series of consecutive nephrectomies diagnosed as CCRCC and found 37 tumors with morphologic overlap between CCRCC and CCPRCC, identifying 2 patterns. Pattern 1 tumors (N=19) had areas diagnosable as CCRCC admixed with foci having a prominent linear arrangement of nuclei away from the basement membrane imparting a resemblance to CCPRCC; however, other morphologic features commonly seen in CCPRCC (such as branching acini and cystic spaces with papillary tufts) were not typical and, when present, were focal or poorly developed. Pattern 2 (N=18) tumors had 2 discrete areas, one area with an appearance strongly resembling CCPRCC and the other with higher grade nuclei and features diagnosable as CCRCC, sometimes including rhabdoid differentiation, sarcomatoid differentiation, necrosis, and high-stage disease. Four (21%) of the pattern 1 tumors had grade 3 nuclei in the CCRCC-like areas, and 4 were high stage (pT3a). Of the 16 immunostained pattern 1 tumors, all expressed cytokeratin 7 (CK7) at least focally in the CCPRCC-like areas, strongly and diffusely in 9 (56%) cases; 12 (75%) showed negative to focal and/or weak CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, high-molecular-weight cytokeratin, and carbonic anhydrase IX (CA IX) had no significant differential expression between these foci. No cup-like staining pattern was seen with CA IX. Two (11%) patients with pattern 1 tumors developed metastases, and 1 (5%) subsequently died of disease. Eleven (61%) pattern 2 cases had the International Society of Urological Pathology grade 3 nuclei in the CCRCC-like areas, and 7 (39%) were grade 4 (4 of these cases had rhabdoid features; 1 was also sarcomatoid). Of the 16 immunostained pattern 2 tumors, 8 (50%) showed strong diffuse CK7 expression in the CCPRCC-like areas, and 9 (56%) showed complete lack of CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, and high-molecular-weight cytokeratin did not have significant differential expression. Membranous expression of CA IX, typically strong and diffuse, was identified in both the CCPRCC-like and CCRCC-like areas in all cases tested (with a cup-like pattern at least focally in the CCPRCC-like areas of 10 [63%] pattern 2 cases). Five (28%) patients with pattern 2 tumors had distant metastases, 3 (17%) of whom subsequently died of disease. Renal cell carcinomas with areas resembling both CCRCC and CCPRCC occur. Some can have high-grade and high-stage foci, and aggressive clinical outcomes are seen. Given this malignant potential, we would presently diagnose such cases as CCRCC. These 2 patterns of renal neoplasia underscore the need for caution in diagnosing CCPRCC on limited sampling, reserving the diagnosis for those tumors that strictly fulfill both morphologic and immunohistochemical criteria.
透明细胞乳头状肾细胞癌(CCPRCC)最近被纳入国际泌尿病理学会温哥华肾肿瘤分类,作为肾细胞癌的一种亚型,其在形态学、免疫组织化学和遗传学上与透明细胞肾细胞癌(CCRCC)和乳头状肾细胞癌均不同。在我们的临床实践中,我们观察到具有CCPRCC和CCRCC重叠组织学特征的肿瘤;因此,我们的目的是描述这些肿瘤的形态学、免疫组织化学和临床特征。我们检查了一系列连续诊断为CCRCC的肾切除术病例,发现37例肿瘤具有CCRCC和CCPRCC之间的形态学重叠,识别出两种模式。模式1肿瘤(N = 19)具有可诊断为CCRCC的区域,与具有远离基底膜的细胞核突出线性排列的灶混合,类似于CCPRCC;然而,CCPRCC中常见的其他形态学特征(如分支腺泡和带有乳头簇的囊性间隙)并不典型,若存在则为局灶性或发育不良。模式2(N = 18)肿瘤有两个离散区域,一个区域外观强烈类似于CCPRCC,另一个区域具有更高分级的细胞核和可诊断为CCRCC的特征,有时包括横纹肌样分化、肉瘤样分化、坏死和高分期疾病。模式1肿瘤中有4例(21%)在CCRCC样区域具有3级细胞核,4例为高分期(pT3a)。在16例免疫染色的模式1肿瘤中,所有肿瘤在CCPRCC样区域至少局灶性表达细胞角蛋白7(CK7),9例(56%)为强弥漫性表达;12例(75%)在CCRCC样区域显示阴性至局灶性和/或弱CK7表达。CD10、α - 甲基酰基辅酶A消旋酶、高分子量细胞角蛋白和碳酸酐酶IX(CA IX)在这些灶之间无显著差异表达。CA IX未见杯状染色模式。模式1肿瘤患者中有2例(11%)发生转移,1例(5%)随后死于该疾病。模式2病例中有11例(61%)在CCRCC样区域具有国际泌尿病理学会3级细胞核,7例(39%)为4级(其中4例具有横纹肌样特征;1例也有肉瘤样特征)。在16例免疫染色的模式2肿瘤中,8例(50%)在CCPRCC样区域显示强弥漫性CK7表达,9例(56%)在CCRCC样区域显示完全缺乏CK7表达。CD10、α - 甲基酰基辅酶A消旋酶和高分子量细胞角蛋白无显著差异表达。在所有检测病例中,CA IX的膜性表达在CCPRCC样和CCRCC样区域均典型地为强弥漫性(10例[63%]模式2病例在CCPRCC样区域至少局灶性呈杯状模式)。模式2肿瘤患者中有5例(28%)发生远处转移,其中3例(对应17%)随后死于该疾病。存在类似于CCRCC和CCPRCC的肾细胞癌区域。一些可能具有高级别和高分期灶,且可见侵袭性临床结果。鉴于这种恶性潜能,我们目前会将此类病例诊断为CCRCC。这两种肾肿瘤模式强调了在有限取材时诊断CCPRCC需谨慎,将诊断保留给那些严格满足形态学和免疫组织化学标准的肿瘤。